{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:02:49Z","timestamp":1784516569825,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: T-cell-redirecting immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs), have transformed the treatment of relapsed\/refractory multiple myeloma (RRMM). However, pivotal registration trials routinely excluded patients with significant renal impairment (RI), creating a critical evidence gap in a population where kidney disease affects 20\u201350% of patients at diagnosis. Direct comparisons of outcomes across the estimated glomerular filtration rate (eGFR) spectrum for both modalities are lacking. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, a federated electronic health record research platform. Adult patients with RRMM treated with CAR-T therapy (idecabtagene vicleucel or ciltacabtagene autoleucel) or BsAbs (teclistamab, elranatamab, or talquetamab) were stratified by baseline renal function: severe RI (eGFR &lt;30 mL\/min\/1.73 m2), moderate RI (eGFR 30\u201360 mL\/min\/1.73 m2), and preserved renal function (eGFR &gt;60 mL\/min\/1.73 m2). Propensity score matching (PSM) (1:1), adjusted for key clinical and demographic covariates, was performed for each comparison within each therapy type. Long-term outcomes (all-cause mortality and time to next treatment [TTNT]) were assessed at 1, 2, and 3 years. Overall survival (OS) was additionally evaluated using Kaplan\u2013Meier analysis. Short-term safety outcomes were assessed at 1, 3, and 6 months. Results: A total of 2716 CAR-T and 3376 BsAb recipients were identified. After matching, 281 pairs (severe RI vs. preserved) and 878 pairs (moderate RI vs. preserved) were analyzed in the CAR-T cohort; 645 and 1158 pairs, respectively, were analyzed in the BsAb cohort. Neither severe nor moderate RI was significantly associated with increased mortality or shorter TTNT after either CAR-T or BsAb therapy. However, patients with RI experienced significantly higher rates of anemia, thrombocytopenia, and acute kidney injury (AKI) across both modalities. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and neutropenia rates were comparable across renal strata. In the BsAb cohort, infections were transiently elevated at 1 month in the severe RI group (RR 1.29; 95% CI 1.06\u20131.58; p = 0.011) but equilibrated by 3 months. Conclusions: In this retrospective analysis, renal impairment was not associated with inferior survival outcomes following CAR-T therapy or BsAb treatment in RRMM, suggesting that RI alone should not preclude the use of these agents. However, RI conferred increased hematologic toxicity and AKI risk, warranting enhanced supportive care and monitoring. These findings support broadening access to T-cell-redirecting immunotherapies for patients with RI with appropriate surveillance, though prospective validation is needed.<\/jats:p>","DOI":"10.3390\/cancers18142311","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:32:08Z","timestamp":1784514728000},"page":"2311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Anushareddy","family":"Muddasani","sequence":"first","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2699-1741","authenticated-orcid":false,"given":"Carolina D.","family":"Schinke","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of Multiple Myeloma-Related Renal Impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-Cell Immunotherapy in Patients with Multiple Myeloma: Practical Considerations from the European Myeloma Network","volume":"12","author":"Moreau","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of Acute Kidney Injury in Symptomatic Multiple Myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1007\/s00277-024-05860-3","article-title":"Update on Kidney Injury Caused by Multiple Myeloma","volume":"103","author":"Wang","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute Kidney Injury in Patients with Cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Multiple Myeloma with Renal Impairment","volume":"109","author":"Sidana","year":"2023","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Grieb, N., Wiemers, T., Born, P., Fandrei, D., Fischer, L., Ferle, M., Franke, S., Keller, J., Wang, S.Y., and Jentzsch, M. (Transplant. Cell. Ther., 2026). Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma, Transplant. Cell. Ther., in press.","DOI":"10.1016\/j.jtct.2026.05.022"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Filippatos, C., Ntanasis-Stathopoulos, I., Briasoulis, A., Malandrakis, P., Terpos, E., and Gavriatopoulou, M. (2026). Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed\/Refractory Multiple Myeloma Patients. Cancers, 18.","DOI":"10.3390\/cancers18061013"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mahadevia, H., Modi, K., Arya, Y., Syal, A., El-Husseiny, K.M., Modi, S., Bansal, V., Vodnala, D., Khumri, T., and Cossor, F. (2026). Impact of Chronic Kidney Disease on Toxicity Patterns and Economic Burden in CAR T-Cell Therapy for Multiple Myeloma: A National Analysis. J. Clin. Oncol., 44.","DOI":"10.1200\/JCO.2026.44.16_suppl.e19536"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/ajh.70312","article-title":"The Role of Bispecific Antibodies in Relapsed\/Refractory Multiple Myeloma with Renal Impairment: A Systematic Review","volume":"101","author":"Manganas","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1182\/bloodadvances.2025016059","article-title":"Teclistamab for Patients with Heavily Pretreated Relapsed\/Refractory Multiple Myeloma and Renal Impairment","volume":"9","author":"Dima","year":"2025","journal-title":"Blood Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/10781552251341235","article-title":"Using Bispecific Antibodies in a Patient with Peritoneal Dialysis for Relapsed Multiple Myeloma","volume":"31","author":"Jiang","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1007\/s00277-025-06689-0","article-title":"Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Case Report of Elranatamab and a Literature Review","volume":"104","author":"Ogiya","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hoffmann, M., Jeker, B., Huynh-Do, U., Banz, Y., Godau, J., Weber, E., Bacher, U., and Pabst, T. (2025). Elranatamab for Relapsed\/Refractory Multiple Myeloma with Severe Renal Impairment Requiring Hemodialysis. Hematol. Oncol., 43.","DOI":"10.1002\/hon.70120"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s11255-025-04503-4","article-title":"Nephrotoxicity of CAR-T Therapy in Patients with Relapsed and Refractory Multiple Myeloma","volume":"57","author":"Chen","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/ndt\/gfaf004","article-title":"Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma Treated with Teclistamab versus CAR-T Cells","volume":"40","author":"Charkviani","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000536194","article-title":"CAR-T Cell Therapy: Advances in Kidney-Related Diseases","volume":"10","author":"Wu","year":"2024","journal-title":"Kidney Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.0000000896","article-title":"Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions","volume":"37","author":"Song","year":"2026","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-0716-1507-2_15","article-title":"Protein-Bound Uremic Toxins and Immunity","volume":"Volume 2325","author":"Gigante","year":"2021","journal-title":"Cytotoxic T-Cells"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections Following Bispecific Antibodies in Myeloma: A Systematic Review and Meta-Analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A Systematic Review and Meta-Analysis of Nonrelapse Mortality after CAR T Cell Therapy","volume":"30","author":"Tix","year":"2024","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on Prevention of Infections during Chimeric Antigen Receptor T-cell and Bispecific Antibody Therapy in Multiple Myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S.P., Lesokhin, A.M., Lonial, S., Ludwig, H., and Moreau, P. (2023). Monitoring, Prophylaxis, and Treatment of Infections in Patients with MM Receiving Bispecific Antibody Therapy: Consensus Recommendations from an Expert Panel. Blood Cancer J., 13.","DOI":"10.1038\/s41408-023-00879-7"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and Management of Adverse Events during Treatment with Bispecific Antibodies and CAR T Cells in Multiple Myeloma: A Consensus Report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:48:00Z","timestamp":1784515680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":30,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142311"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142311","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}